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Abstract
Background: The identification of new risk factors for coronary artery disease (CAD) is increasingly sought in an
effort to tackle this threatening disease. β2-microglobulin (B2M) is reported to associate with peripheral arterial
disease and adverse cardiovascular outcomes. However, the association between B2M and cardiovascular disease
remains under-researched. This study evaluated the effects of B2M on CAD without renal dysfunction.
Methods: One thousand seven hundred sixty-two subjects (403 non-CAD subjects and 1,359 CAD subjects) were
investigated. Fasting samples were collected to determine B2M level. The Gensini and SYNTAX scores were used to
assess the severity of CAD.
Results: CAD subjects were significantly higher in serum B2M level comparing with non-CAD subjects (1.25 ± 0.46
vs 1.14 ± 0.28 mg/L, p < 0.001). Serum B2M level was a risk factor of CAD after adjusting potential confounders
(Odds Ratio (OR) = 2.363, 95% confidence interval (CI): 1.467–3.906, p = 0.001). Receiver operating characteristics
(ROC) showed B2M level moderately predicted diagnosis of CAD (the area under the ROC curve (AUC) = 0.608,
95% CI: 0.577–0.639, p < 0.001). Furthermore, serum B2M level was positively associated with Gensini score system,
SYNTAX score system and the number of disease vessels (NDV ≥ 2).
Conclusions: The significant association between serum B2M and CAD suggests that B2M could be a biomarker for
CAD.
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Background
Coronary artery disease (CAD) has remained the first
death burden globally between 2000 and 2012. It was re-
sponsible for over 7.4 million deaths in 2012. Although,
both genders of all ages may develop CAD, males and
the elderly are more vulnerable to death causing by
CAD [1, 2]. Quality of life was also remarkably reduced
in CAD patients. Nearly a third patients had angina
attacks at least once per week [3]. Therefore, there is
imperative focus to identify new CAD risk factors. Several
biomarkers, such as C-reactive protein [4, 5], natriuretic
peptides [6, 7] and sensitive cardiac troponins [8, 9] have
been used to predict risk of CAD.
β2-microglobulin (B2M), a low molecular-weight pro-
tein (~11,800 Da), is a component of the major histo-
compatibility complex (MHC) class I molecules on all
nucleated cells [10]. Due to the rapid, simple, reliable, and
inexpensive measurement of B2M, it is commonly used by
clinicians to evaluate conditions such as: dialysis-related
amyloidosis [11], human immunodeficiency virus (HIV)
disease [12], myeloma [13], leukemia [14], and collagen
disease [15]. B2M has been correlated to inflammatory
diseases [16] and is also an estimator of the glomerular fil-
tration rate (GFR) [17].
Recent studies have shown that circulating B2M is
elevated in accordance with the acuteness of disease in
peripheral arterial disease (PAD) patients [18–20]. High
levels of serum B2M was also associated with adverse
cardiovascular outcomes in patients with CAD [21, 22].
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Aysegul Zumrutdal has reported B2M was positively cor-
related with the carotid intima-media thickness (C-IMT)
in haemodialysis patients [23]. However, there is no con-
firming evidence of the relationship between serum B2M
and the severity of CAD. In this study, we examined the
relationship between the concentrations of serum B2M
and severity of CAD.
Methods
Study population
Two thousand two-hundred consecutive subjects admit-
ted to a university hospital with the suspected or already
documented of CAD (included acute coronary syndrome
and stable angina), who underwent selective coronary angi-
ography (CAG) between June 2011 and July 2012, partici-
pated as the candidates for study. A self-administered
questionnaire was conducted (covering items on demo-
graphic, disease history, cigarette and alcohol consumption
(defined as one or more alcoholic drink per week)). Dia-
betes mellitus history was defined as a fasting plasma
glucose level > 126 mg/dL, or 2-h post-load blood
sugar > 200 mg/dL, or glycated hemoglobin (A1c) ≥
6.5%, or using anti-diabetic drugs. Hypertension was
defined as systolic blood pressure (SBP) ≥ 140 mmHg
or diastolic blood pressure (DBP) ≥90 mmHg or tak-
ing anti-hypertensive medications.
A total of 390 subjects were excluded where blood
samples were not measured, or a questionnaire was not
completed. 1,810 subjects with serum β2-microglobulin
and creatinine levels were selected as candidates for fur-
ther study. Among them, 48 subjects with creatinine
levels of ≥ 115 umol/L were removed to exclude the sub-
jects with possibility of renal dysfunction. Finally, 1,762
subjects were included in this study, with 403 non-CAD
subjects (referred to those with normal coronary angiog-
raphy or vessel stenosis <50%), and 1,359 CAD subjects
(those with positive coronary artery angiography and
vessel stenosis ≥ 50%). This observational study complied
with the tenets of the Declaration of Helsinki and was
approved by Clinical Research Ethical Committee of
Hebei Medical University. All informed consents were
signed by participants before conducting.
Laboratory analysis
In all cases, blood samples were drawn following a mini-
mum 12 h overnight fast. All the tests were performed
using standard biochemical techniques to determine the
following parameters: β2-microglobulin (B2M, mg/L),
triglyceride (mmol/L), total cholesterol (mmol/L), high-
density lipoprotein cholesterol (HDL-cholesterol, mmol/L),
low-density lipoprotein cholesterol (LDL-cholesterol,
mmol/L), apolipoprotein-A (g/L), apolipoprotein-B (g/L),
fasting blood glucose (mmol/L), creatinine (umol/L), blood
urea nitrogen (BUN, mmol/L), and uric acid (UA, umol/L).
Coronary angiography
Two experienced interventional cardiologists (M.D. and
M.G.K.) measured quantitative coronary angiography
using the standard Judkins approach. Both had no
knowledge of subjects’ clinical information. Two or
more clinicians cross-checked the CAG reports and
determined the degree of coronary stenosis according to
the American Heart Association standards [24]. Coronary
stenosis was determined to be significant at ≥50%. Left an-
terior descending arteries, left circumflex arteries, and right
coronary arteries were measured to determine the number
and range of stenotic coronary arteries (SCA) (0 to 3-vessel
disease (VD)). 2-VD was independently recorded when cor-
onary stenosis was found in the left main trunk. Stenotic ar-
teries was counted using the scoring systems, Gensini [25]
and SYNTAX [26], to determine the extent of CAD.
Statistical analysis
All subjects were categorized into 4 groups according to
B2M quartile ranges. Data was presented as the mean ± SD
(standard deviation) for scaled measurements or percent-
ages for categorized values. Analysis of variance (ANOVA)
was performed for testing continuous data. Kruskal-Wallis
test was used for not normally distributed outcomes. Cat-
egorical comparison was tested through Chi-square test.
Pearson correlations and Spearman correlations were per-
formed to determine statistically significant factors into
multiple regression model. Biologically relevant factors
were also selected into multiple regression model to exam
the association between B2M and CAD as well as B2M and
Gensini score or SYNTAX score. Receiver operating char-
acteristics (ROC) curve was used to assess the prediction
accuracy of CAD by B2M. Statistically significance was set
as P < 0.05. All the statistical analyses were conducted by
Statistical Package for Social Sciences (SPSS) software (ver-
sion 12 for Windows, SPSS, Inc., Chicago, IL, USA).
Results
Characteristics of the study subjects
One thousand seven hundred sixty-two subjects were eli-
gible for the study (403 non-CAD subjects and 1,359 CAD
subjects). CAD subjects were elder than non-CAD subject
(58.60 ± 9.59 vs 55.65 ± 9.68, p < 0.001). More males were
observed in the CAD subjects (70.6% vs 47.8%, p < 0.001).
The prevalence of smoking, drinking, hypertension, dia-
betes mellitus, and acute myocardial infarction (AMI) in
CAD subjects was higher than non-CAD subjects (Table 1).
CAD subjects also had a higher value of creatinine concen-
trations, blood urea nitrogen (BUN), uric acid (UA), trigly-
ceride, apolipoprotein-A and apolipoprotein-B. B2M levels
were significantly lower in non-CAD subjects (1.14 ± 0.28
vs 1.25 ± 0.46 mg/L, p < 0.001; Fig. 1a).
All 1,762 subjects were also categorized into 4 groups
based on B2M quartile ranges (Additional file 1: Figure S1):
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1st quartile (<1.00 mg/L), 2nd quartile (1.00-1.17 mg/L),
3rd quartile (1.18-1.35 mg/L), and 4th quartile
(>1.35 mg/L). To eliminate the possibility of renal dys-
function, subjects only in the normal range of creatinine
were included (Additional file 2: Figure S2). As shown in
Table 2, we compared the main baseline demographic,
clinical and angiographic characteristics between the four
quartiles. There was an increasing in B2M level with aging
(p < 0.001). Significant measurements were also included
drinking, hypertension, diabetes mellitus, myocardial in-
farction, baseline apolipoprotein-A, HDL-C, creatinine,
uric acid (UA) and blood urea nitrogen (BUN) (Table 2).
Relationship between serum B2M and prevalence of CAD
In univariate analysis, age, gender, smoking, drinking,
hypertension, diabetes mellitus and AMI were statisti-
cally associated with CAD. Further, clinical predictors
(heart failure, hypertension and heart rate (HR)) and bio-
chemical risk factors (creatinine, BUN, UA, TG, TC, HDL-
C, LDL-C, apolipoprotein-A, apolipoprotein-B, and B2M)
were involved into multiple logistic regression model. After
adjusted all the confounders, B2M (odds ratio, OR = 2.363,
95% confidence interval (CI): 1.467–3.906, p = 0.001),
gender (OR = 2.247, CI: 1.668–3.041, p < 0.001), age
(OR = 1.035, CI: 1.021–1.050, p < 0.001), smoking (OR =
1.865, CI: 1.336–2.62, p < 0.001), hypertension (OR =
1.382, CI: 1.074–1.792, p = 0.014), diabetes (OR = 2.278,
CI: 1.532–3.541, p < 0.001), AMI (OR = 6.224, CI: 2.272–
25.708, p = 0.02) and HDL-C (OR = 0.626, CI: 0.479–
0.806, p < 0.001) were predictors of CAD (Table 3).
The correlation of B2M levels and prevalence of
CAD was further confirmed in all four quartiles of
B2M levels (CAD prevalence in B2M quartiles: 68.1%
vs 75.7% vs 79.1% vs 86.1%, OR (95%CI) =1.432
(1.288–1.602), p < 0.001, Fig. 2a, Table 2). The positive
Table 1 Clinical and biochemical characteristics of the study
subjects
Non-CAD (n = 403) CAD (n = 1,359) p-value
Age (years) 55.65 ± 9.68 58.60 ± 9.59 <0.001
Gender (male, %) 47.8 70.6 <0.001
Smoking (%) 18.9 39.4 <0.001
Drinking (%) 15.9 25.8 <0.001
Hypertension (%) 47.8 63.5 <0.001
Diabetes (%) 9.2 19.4 <0.001
AMI (%) 1.2 7.6 <0.001
HF (%) 0.5 0.7 0.992
SBP 131.54 ± 18.56 133.44 ± 21.22 0.108
DBP 81.29 ± 12.08 81.15 ± 20.89 0.378
HR (bpm) 68.04 ± 14.68 70.49 ± 13.08 0.008
Creatinine (umol/L) 66.58 ± 15.25 71.2 ± 15.3 <0.001
BUN (mmol/L) 5.25 ± 4.2 6.38 ± 18.96 <0.001
UA (umol/L) 285.44 ± 137.57 306.84 ± 179.28 <0.001
Glu 7.44 ± 31.96 6.48 ± 18.86 <0.001
TG (mmol/L) 1.6 ± 1.01 2 ± 5.19 0.002
TC (mmol/L) 4.36 ± 1.83 4.67 ± 11.29 0.424
HDL-C (mmol/L) 1.49 ± 5.22 1.09 ± 0.45 0.000
LDL-C (mmol/L) 2.58 ± 0.77 2.95 ± 9.76 0.055
Apo-A (g/L) 1.37 ± 0.27 1.3 ± 0.71 <0.001
Apo-B (g/L) 0.88 ± 0.25 1.15 ± 4.9 <0.001
B2M (mg/L) 1.14 ± 0.28 1.25 ± 0.46 <0.001
Gensini score 0.5 ± 1.69 39.34 ± 34.66 <0.001
CAD coronary artery disease, AMI acute myocardial infarction, HF heart failure,
SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BUN
blood urea nitrogen, UA uric acid, Glu blood glucose, TG Triglycerides, TC total
cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol, Apo-A Apolipoprotein A, Apo-B Apolipoprotein B, B2M
β2-microglobulin. Data are means ± SD
a b
Fig. 1 B2M levels between patients with CAD (n = 1,359) and those without CAD (n = 403). a Comparison of serum B2M levels in non-CAD vs
CAD. b Comparison of serum B2M levels according to the number of stenotic coronary arteries (NVD = 0, 1, 2, and 3)
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trend was also observed with increased number of stenotic
arteries (p < 0.001, Table 2, Additional file 3: Figure S3).
The ability of correctly diagnosing CAD and non-CAD
subject according to B2M was assessed using the
receiver operating characteristics (ROC) curve. B2M
showed a moderate predictive ability for CAD according
to the area under the ROC curve (AUC = 0.608,95% CI:
0.577–0.639, p = 0.001) (Fig. 3).
Relationship between serum B2M and clinical or
biochemical parameters
B2M was positively correlated with age (Pearson Correl-
ation Coefficient (rp) rp = 0.207, p < 0.001), SBP (rp = 0.073,
p = 0.004), creatinine (rp = 0.203, p < 0.001) and UA
(rp = 0.113, p < 0.001) (Table 4). In multiple regression, age
(standardized β = 0.197, p < 0.001), SBP (standardized
β = 0.057, p = 0.020), creatinine (standardized β = 0.179,
p < 0.001), and UA (standardized β = 0.095, p < 0.001)
were still associated with B2M.
Relationship between serum B2M and severity of CAD
B2M was positively correlated with Gensini score
(Spearman Correlation Coefficient (rs) rs = 0.169, p < 0.001;
Fig. 4a). We further assessed the relationship by a multiple
stepwise regression model adjusting age, gender,
smoking, hypertension, diabetes mellitus and AMI.
Table 2 Baseline clinical and angiographic features based on quartiles of B2M










Age (years) 53.85 ± 9.44 56.49 ± 9.12 60.38 ± 8.53 61.58 ± 9.55 <0.001
Gender (male, %) 63.0 68.7 65.8 63.9 0.285
Smoker (%) 33.3 38.3 34.9 32.0 0.242
Drinker (%) 25.5 28.0 21.7 18.3 0.005
Hypertension (%) 52.9 59.0 61.3 67.7 <0.001
Diabetes (%) 15.2 16.0 15.5 22.1 0.022
AMI (%) 3.6 5.9 8.5 6.9 0.018
HF (%) 0.4 0.5 0.9 0.7 0.751
Baseline blood features
TG (mmol/L) 1.86 ± 1.33 2.01 ± 5.09 2.12 ± 7.51 1.64 ± 1.03 0.228
TC (mmol/L) 4.39 ± 0.99 4.42 ± 1.01 4.39 ± 1.88 5.26 ± 20.39 0.044
HDL-C (mmol/L) 1.14 ± 0.49 1.38 ± 4.98 1.1 ± 0.33 1.09 ± 0.58 0.000
LDL-C (mmol/L) 2.65 ± 0.82 2.74 ± 0.92 2.62 ± 0.85 3.49 ± 17.6 0.295
Apo-A (g/L) 1.31 ± 0.29 1.41 ± 1.15 1.27 ± 0.26 1.25 ± 0.38 <0.001
Apo-B (g/L) 1.25 ± 6.59 1.19 ± 5.19 0.94 ± 0.4 0.94 ± 0.36 0.730
Creatinine (umol/L) 64.13 ± 13.68 68.48 ± 13.12 71.36 ± 15.56 77.4 ± 16.13 <0.001
BUN (mmol/L) 5.78 ± 14.45 5.15 ± 1.26 6.89 ± 19.98 6.74 ± 23.13 <0.001
UA (umol/L) 272.97 ± 76.96 299.38 ± 88.34 300.06 ± 120.89 338.75 ± 301.73 <0.001
Angiographic features
CAD (%) 68.1 75.7 79.1 86.1 <0.001
Severe CADa (%) 29.4 46.5 52.2 82.2 <0.001
Number of stenotic arteries <0.001
0 (%) 37.2 27.1 22.3 21.7
1 (%) 26.6 28.0 25.6 21.3
2 (%) 22.1 25.2 26.2 24.5
3 (%) 14.1 19.8 25.9 32.6
Gensini score 24.94 ± 31.95 28.31 ± 34.42 30.02 ± 32.54 39.5 ± 37.73 <0.001
aSevere CAD defined as the patients with number of stenotic arteries ≥2. Data are means ± SD
CAD coronary artery disease, AMI acute myocardial infarction, HF heart failure, SBP systolic blood pressure, DBP, diastolic blood pressure, HR heart rate, BUN blood
urea nitrogen, UA uric acid, TG Triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Apo-A Apolipoprotein
A, Apo-B Apolipoprotein B, B2M β2-microglobulin
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After adjustment, serum B2M was still significantly
associated with the Gensini score (β = 0.078, 95% CI:
0.029–0.127, p = 0.002; Table 5).
We also performed the analysis in SYNTAX score. B2M
was correlated with SYNTAX score (rs = 0.239, p < 0.001,
Fig. 4b). In multiple stepwise regression, SYNTAX score
was increased 0.077 as B2M level increased 1 mg/L
(β = 0.077, 95% CI: 0.029–0.126, p = 0.002; Table 6).
Proportion of severe CAD was increased with higher
B2M levels (29.4% vs 46.5% vs 52.2% vs 82.2%, p < 0.001,
Fig. 2b, Table 2). B2M increased with the number of sten-
otic vessels with the lowest level in NVD of 0 (1.14 ± 0.28,
1.22 ± 0.61, 1.24 ± 0.32, 1.29 ± 0.39 mg/L in NVD of 0, 1,
2, and 3, respectively (Fig. 1b)).
Discussion
Coronary artery disease (CAD) is associated with a high
rate of mortality. Scientists and researchers have
attempted to reduce the burden by identifying the rela-
tionship between biomarkers and CAD. In recent years,
several biomarkers - C-reactive protein [4, 5], natriuretic
peptides [6, 7] and sensitive cardiac troponins [8, 9] - have
been used to estimate the risk of CAD. Some researchers
have also investigated the relationship between coagula-
tion factors (such as Fibrinogen, Thrombin, and Tissue
a
b
Fig. 2 Bar graphs show the prevalence of CAD (a) and severe CAD
(b) according to B2M quartiles
Fig. 3 ROC curve analyses for predictive values of B2M in
detecting CAD

















SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BUN
blood urea nitrogen, UA uric acid, Glu blood glucose, TG Triglycerides, TC total
cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol, Apo-A Apolipoprotein A, Apo-B Apolipoprotein B
Table 3 Multiple stepwise regression analysis showing variables
independently associated with CAD
Odds Ratio (OR) 95% CI p-value
B2M 2.363 1.467–3.906 0.001
Gender 2.247 1.668–3.041 <0.001
Age 1.035 1.021–1.050 <0.001
Smoking 1.865 1.336–2.620 <0.001
Hypertension 1.382 1.074–1.792 0.014
Diabetes 2.278 1.523–3.514 <0.001
AMI 6.224 2.272–25.708 0.002
HDL-C 0.626 0.479–0.806 <0.001
CAD coronary artery disease, B2M β2-microglobulin, AMI acute myocardial infarction,
HDL-C high-density lipoprotein cholesterol
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Factor), development of atherosclerosis and thrombotic
complication [27, 28], so as to optimize the treatment of
CAD patients.
This is the first study to reveal the effects of B2M plas-
matic level in the extent of coronary atherosclerosis in a
large consecutive Chinese population. Our study demon-
strated the B2M was not only associated with CAD
prevalence, but also positively correlated with severity of
CAD. One study has reported the correlation between
B2M and carotid atherosclerosis severity in renal failure
patients [23]. However, biased study population and lim-
ited the sample size constrained the conclusion to ex-
tend to other population.
The protein B2M is a non-glycosylated polypeptide
consisted of 99 amino acids, and it can interact with and
stabilize the tertiary structure of the MHC I α-chain
[29]. B2M is not directly attached to cell membranes,
due to its non-covalently association with the α-chain.
After released inside the cell or detached from cell sur-
faces, B2M is then largely removed via glomerular filtra-
tion. It is this process that allows the glomerular
filtration rate to be estimated [30]. In comparison to
healthy subjects (serum B2M <2ug/mL, and urinary ex-
cretion <400ug/24 h [29]), patients on dialysis have
greatly elevated B2M levels which contribute to amyloid
deposition and cardiovascular dysfunction [31]. Auto-
immune, neoplastic, and infectious diseases, such as
multiple myeloma, lymphoma, and Sjogren’s syndrome
have also reported to associate with increased plasma
levels of B2M [32–34].
Although the mechanism for the association between
B2M levels and CAD remains to be clarified, the rela-
tionship between B2M and alterations in vascular struc-
tures, immunity and inflammation disorders, suggests
B2M may contribute to vascular inflammation [35, 36].
Atherosclerotic syndromes are also predominantly asso-
ciated with an inflammatory response [37, 38], which
leads the relationship between B2M and CAD. Further-
more, studies have shown that B2M concentrations were
significant non-renal predictors of cardiovascular out-
comes, renal outcomes, and mortality [39–43].
Researchers have provided association between B2M
and CAD risk factors [22, 35], and left atrial size [44].
Liu YS found a positive relationship of B2M to serum
levels of creatinine and a negative relationship to cre-
atinine clearance rate [44]. To further build on these
studies, we divided the participants into four quartiles
according to the serum B2M levels, as well as the
number of SCA (0 to 3-VD). We observed the B2M
level was remarkably associated with the prevalence
a b
Fig. 4 Correlation between B2M and the severity of CAD evaluated by either (a) Gensini or (b) SYNTAX score
Table 5 Multiple stepwise regression analysis showing variables
independently associated with Gensini score
Variables Coefficients (β) 95% CI p-value
B2M 0.078 0.029–0.127 0.0019
Gender 0.132 0.077–0.188 <0.001
Age 0.107 0.058–0.157 <0.001
Smoking 0.070 0.015–0.126 0.0125
Hypertension 0.052 0.004–0.101 0.0333
AMI 0.124 0.076–0.172 <0.001
Diabetes 0.105 0.057–0.153 <0.001
B2M β2-microglobulin, AMI acute myocardial infarction
Table 6 Multiple stepwise regression analysis showing variables
independently associated with Syntax score
Variables Coefficients (β) 95% CI p-value
B2M 0.077 0.029–0.126 0.0018
Gender 0.160 0.105–0.215 <0.001
Age 0.154 0.104–0.203 <0.001
Smoking 0.049 −0.006–0.103 0.0802
Hypertension 0.062 0.014–0.109 0.0114
AMI 0.149 0.101–0.196 <0.001
Diabetes 0.109 0.061–0.156 <0.001
B2M β2-microglobulin, AMI acute myocardial infarction
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of severe CAD (29.4% for B2M ≤1 mg/L, while 82.2%
for B2M >1.35 mg/L). Another important observation
was that the B2M level was positively correlated with
creatinine, especially in the subjects with severe CAD.
Liu YS also found a linear trend between uric acid
and B2M, indicating a potential link between the kid-
ney and the heart [44].
There were some limitations in this study. First, we
did not have a control group for the CAD or suspected
diagnosis of CAD. Although the participants with number
of SCA of 0 were treated as control group (non-CAD), all
subjects in our study were consecutive at least with the
suspected diagnosis of CAD. Therefore, the control group
participants may be with a high risk for CAD. Second, this
is an observational study, the follow up outcomes of B2M
levels on cardiovascular was unavailable.
Our study reveals a strong association between level of
serum B2M and CAD (both prevalence and severity) in
subjects without renal dysfunction. These findings pro-
vide support to the potential of B2M as a biomarker for
CAD. Further studies are need to ensure the potential
benefits of B2M level for CAD in clinical routine.
Conclusions
The significant association between serum B2M and
CAD suggests that B2M could be a biomarker for CAD.
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